Kanbay Mehmet, Akcay Ali, Delibasi Tuncay, Uz Burak, Kaya Arif, Koca Cemile, Turgut Faruk, Bavbek Nuket, Uz Ebru, Duranay Murat, Yigitoglu Ramazan
Department of Nephrology, Fatih University School of Medicine, Ankara, Turkey.
Adv Ther. 2007 Mar-Apr;24(2):346-52. doi: 10.1007/BF02849903.
It is well known that epoetin alfa increases serum endothelin (ET)-1 and blood pressure. No data are available, however, on the effects of darbepoetin alfa on serum ET-1 and blood pressure. This study was conducted to compare the effects of darbepoetin alfa and epoetin alfa on serum ET-1 and blood pressure in patients on hemodialysis (HD). A total of 42 patients on HD were included in the study. Serum samples for measuring levels of ET-1 were taken 30 min after administration of epoetin alfa. After blood samples had been taken from all patients, epoetin alfa was changed to darbepoetin alfa. Three months after the start of darbepoetin alfa treatment, blood samples were taken to measure the same parameters. Mean arterial blood pressure was measured before recombinant human erythropoietin (EPO) administration and 30 min after EPO administration while patients were taking epoetin alfa or darbepoetin alfa. Injection of epoetin alfa or darbepoetin alfa significantly increased serum ET-1 levels compared with levels in those patients who were not on EPO therapy (P<.05). When the effects of epoetin alfa on serum ET-1 level were compared with those of darbepoetin alfa, the 2 types of EPO were found to increase serum ET-1 levels similarly (P>.05). Administration of epoetin alfa or darbepoetin alfa increased systolic and diastolic blood pressures significantly over values in the control group (P<.05). Serum systolic and diastolic blood pressures increased similarly after injection of epoetin alfa or darbepoetin alfa. Administration of darbepoetin alfa increased blood pressure in patients on HD in a way that was positively correlated with enhanced ET-1 release; a similar correlation was noted with epoetin alfa.
众所周知，促红细胞生成素α可升高血清内皮素（ET）-1水平并升高血压。然而，关于达比泊汀α对血清ET-1水平和血压影响的数据尚无报道。本研究旨在比较达比泊汀α和促红细胞生成素α对血液透析（HD）患者血清ET-1水平和血压的影响。共有42例HD患者纳入本研究。在给予促红细胞生成素α 30分钟后采集用于测定ET-1水平的血清样本。在采集完所有患者的血样后，将促红细胞生成素α换为达比泊汀α。达比泊汀α治疗开始3个月后，采集血样以测量相同参数。在患者使用促红细胞生成素α或达比泊汀α时，于重组人促红细胞生成素（EPO）给药前及给药后30分钟测量平均动脉血压。与未接受EPO治疗的患者相比，注射促红细胞生成素α或达比泊汀α显著升高了血清ET-1水平（P<0.05）。当比较促红细胞生成素α和达比泊汀α对血清ET-1水平的影响时，发现这两种EPO升高血清ET-1水平的作用相似（P>0.05）。与对照组相比，促红细胞生成素α或达比泊汀α给药显著升高了收缩压和舒张压（P<0.05）。注射促红细胞生成素α或达比泊汀α后，血清收缩压和舒张压升高幅度相似。达比泊汀α给药使HD患者血压升高，且与ET-1释放增强呈正相关；促红细胞生成素α也有类似的相关性。
